D2R | DNA to RNA (original) (raw)
An inclusive Canadian approach to genomic-based RNA therapeutics
The time is now for discovery and development of genome-guided, RNA-based precision medicines for Canada and for the world. With a landmark $165 million investment from the Canada First Research Excellence Fund and additional support from the Quebec Government and philanthropic and industry partners, McGill’s world-leading research initiative DNA to RNA (D2R) will develop revolutionary genomic-based RNA medicines for all.
D2R's vision for Canada
Create groundbreaking medical treatments
D2R will improve health through rapid deployment of new lower cost medical treatments for previously “undruggable” pharmaceutical targets and untreated medical conditions.
Tackle societal and policy issues
D2R will address unmet clinical needs of equity-deserving groups, including Canada’s Indigenous populations by engaging with patients, their families and patient organizations.
Accelerate “next-generation” drug development
D2R will catalyze Canadian pharma/biotech to create a major international hub for “next-generation” drug development, industry partnerships and startups.